At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 316 enrolled
Drug / intervention
Ixekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab and Placebo for Spondyloarthritis. Completed, enrolled 316 participants across 99 sites in 17 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpondyloarthritis
CountriesArgentina, Brazil, Canada, Finland, France, Germany, Israel, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartApr 2016
Primary CompletionMay 2018
Study CompletionMay 2019
TodayJul 2026
First PostedMar 2, 2016
Enrollment StartApr 12, 2016
Primary CompletionMay 18, 2018
Study CompletionMay 3, 2019
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 10.3 years ago
Interventions
Ixekizumabdrug
Administered SC
Placebodrug
Administered SC